Cargando…
Betrixaban for prevention of venous thromboembolism in acute medically ill patients
Venous thromboembolism (VTE) is a common, potentially preventable cause of morbidity and mortality among acute medically ill patients. More than half of VTE events in this population occur after hospital discharge. Thus, providing extended-duration VTE prophylaxis from in-hospital through the post-d...
Autores principales: | Beyer-Westendorf, Jan, Verhamme, Peter, Bauersachs, Rupert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016607/ https://www.ncbi.nlm.nih.gov/pubmed/29977165 http://dx.doi.org/10.1093/eurheartj/suy017 |
Ejemplares similares
-
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism
por: Chan, Noel C, et al.
Publicado: (2015) -
Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients
por: Cohen, Alexander T
Publicado: (2018) -
Pharmacological properties of betrixaban
por: Huisman, Menno V, et al.
Publicado: (2018) -
Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014) -
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)